Trial Profile
An open-label, randomized, two treatment, cross over, single dose study to evaluate bioequivalence between fixed-dose combination of 300/5/25 mg aliskiren/amlodipine/hydrochlorothiazide (HCTZ) tablet and free combination of market formulations of the 300 mg aliskiren, 5 mg amlodipine and 25 mg (HCTZ) in healthy subjects.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2016
Price :
$35
*
At a glance
- Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren; Amlodipine; Hydrochlorothiazide
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Novartis
- 08 Feb 2010 New trial record